

Category	#	Recommendation	Strength of recommen	Quality of evidence	% agreement
ANTI-TNF	Q6	Revised Title: Infliximab as a second-line anti-TNF agent after failure or inability to use approved biologics Revised Recommendation: In patients with moderate-to-severe HS who have failed or cannot use approved biologics for HS, and in whom anti-TNF therapy is desired, we suggest using off-label infliximab as a second-line anti-TNF agent.	Conditional	Moderate	93,75%
	Q9	Revised Title: Certolizumab as an alternative anti-TNF option after approved biologics Revised Recommendation: In patients with moderate-to-severe HS who have failed or are unable to use approved biologics for HS, and in whom anti-TNF therapy is desired, we suggest considering off-label certolizumab pegol, particularly in pregnancy.	Conditional	Low	81,25%
ANTI-IL-17	Q13	Revised Title: Off-label IL-17 inhibitors after failure of approved biologics Revised Recommendation: In patients with moderate-to-severe HS who have failed or cannot use approved biologics for HS, and in whom IL-17 inhibitor therapy is desired, we suggest using off-label IL-17 inhibitors.	Conditional	Low	81,25%
ANTI-IL-1	Q14	Revised Title: Anakinra as an IL-1 inhibitor option, after use of approved biologics Revised Recommendation: In patients with moderate-to-severe HS who have failed or cannot use approved biologics for HS, and in whom IL-1 inhibitor therapy is desired, we suggest considering off-label anakinra, particularly in patients with auto-inflammatory features.	Conditional	Moderate	87,50%
ANTI-IL-12/23	Q16	Revised Title: Ustekinumab as an alternative treatment for selected patients with HS Revised Recommendation: In patients with moderate-to-severe HS who have failed or are unable to use approved biologics for HS, and in whom IL-12/23 blockade is desired, we suggest that off-label ustekinumab may provide benefit particularly in patients with concurrent inflammatory bowel disease.	Conditional	Low	87,50%